LICENSE AGREEMENTLicense Agreement • March 9th, 2022 • Keros Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”) is entered into as of February 10, 2022 (the “Amendment Effective Date”), by and between Keros Therapeutics, Inc., corporation organized and existing under the laws of Delaware and having a place of business at 99 Hayden Avenue, Suite 120, Building E, Lexington, MA 02421 (“Keros”), and Hansoh (Shanghai) Healthtech Co., Ltd., a corporation organized and existing under the laws of the People’s Republic of China having a place of business at Room 101, No.287 Xiangke Road and No.1158 Haike Road, China (Shanghai) Pilot Free Trade Zone, China (“Hansoh”). Keros and Hansoh are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO THE EXECUTIVE EMPLOYMENT AGREEMENT OF SIMON COOPERExecutive Employment Agreement • March 9th, 2022 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This First Amendment to the Executive Employment Agreement of Simon Cooper the (“Amendment”) is entered into this 1st day of January, 2022 (the “Effective Date”), by and between Simon Cooper (the “Executive”) and Keros Therapeutics, Inc. (the “Company”).
FIRST AMENDMENT TO THE EXECUTIVE EMPLOYMENT AGREEMENT OF JENNIFER LACHEYExecutive Employment Agreement • March 9th, 2022 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This First Amendment to the Executive Employment Agreement of Jennifer Lachey the (“Amendment”) is entered into this 1st day of January, 2022 (the “Effective Date”), by and between Jennifer Lachey (the “Executive”) and Keros Therapeutics, Inc. (the “Company”).
FIRST AMENDMENT TO THE EXECUTIVE EMPLOYMENT AGREEMENT OF KEITH REGNANTEExecutive Employment Agreement • March 9th, 2022 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This First Amendment to the Executive Employment Agreement of Keith Regnante the (“Amendment”) is entered into this 1st day of January, 2022 (the “Effective Date”), by and between Keith Regnante (the “Executive”) and Keros Therapeutics, Inc. (the “Company”).
